Welcome to our dedicated page for ASCENTAGE PHARMA GROUP INTERNATIONAL SEC filings (Ticker: AAPG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ascentage Pharma Group International furnishes SEC filings as a foreign private issuer reporting under Form 6-K and indicating annual reporting on Form 20-F. The filings document press releases and Hong Kong Stock Exchange announcements for annual results, oncology pipeline updates, clinical and preclinical presentation materials, and changes in corporate administration.
The company’s filing record also includes Hong Kong annual report and environmental, social and governance materials, annual general meeting notices, proxy forms, director re-election matters, general mandates to issue or repurchase shares, and supplemental equity-incentive grant proposals under its RSU and post-IPO share option schemes.
Ascentage Pharma Group International appointed Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer. Dr. Miyara will lead global business development, while Mr. Ziegler will oversee commercialization of products in the United States and other markets outside China; both report to Chairman and CEO Dr. Dajun Yang.
The company describes itself as a global, commercial-stage biopharmaceutical group focused on novel cancer therapies, including the approved products olverembatinib and lisaftoclax and multiple FDA- and EMA-cleared registrational Phase III trials in chronic myeloid leukemia, Ph+ ALL, SDH-deficient GIST, CLL/SLL, AML and higher-risk MDS.
Ascentage Pharma Group International reports that its Chairman and CEO, Dr. Dajun Yang, has been named to The Medicine Maker Power List 2026, ranking No. 3 in the Small Molecules category. The annual list recognizes 60 global leaders driving innovation in drug discovery, development and manufacturing.
The profile highlights Dr. Yang’s more than 30 years in oncology and his role in building Ascentage’s pipeline of apoptosis-targeted small-molecule cancer therapies, including the commercialized products olverembatinib and lisaftoclax. The company is advancing multiple global registrational Phase III studies, including POLARIS and GLORA trials in hematologic cancers and solid tumors.
The disclosure also notes that Ascentage has completed one of the largest business development transactions involving an innovative small molecule company in China and has secured Chinese approvals for its first two products. It has achieved dual primary listings on the Hong Kong Stock Exchange and Nasdaq, described as a first for a biopharmaceutical company listing first in Hong Kong and subsequently in the United States.
Ascentage Pharma Group International plans an at-the-market equity program of up to US$200,000,000 in American depositary shares (ADSs) under an automatic shelf registration statement on Form F-3, filed as a well-known seasoned issuer with the U.S. SEC. Each ADS represents four ordinary shares, and sales would be made on Nasdaq through Citigroup, Deutsche Bank and BTIG under a sales agreement, via ordinary broker transactions or negotiated block trades at market-related prices.
The program relies on the Hong Kong Stock Exchange granting Listing Rules waivers and will not operate during trading blackouts or while the company holds material non-public information. ADS issuance will use the existing general mandate for up to 74,666,950 ordinary shares, which the company expects will keep ATM-related issuance below 20% of currently issued ordinary shares. Any completed ADS offerings will trigger a CSRC filing within three business days under PRC Trial Measures.
Net proceeds, if raised, are intended for research and development, clinical trials and commercialization of drug candidates including Olverembatinib and Lisaftoclax, U.S. commercialization infrastructure, working capital and general corporate purposes, with potential investment in complementary businesses. The company cautions that the registration statement, Listing Rules waivers and the Proposed ATM Program may or may not proceed, and advises shareholders to exercise caution when dealing in its securities.
Ascentage Pharma Group International clarifies the reference date used for its equity incentive plans. The company states that the annual general meeting at which the Scheme Mandate Limit applies to the 2021 Awards, 2022 Awards and Options is May 19, 2025, rather than May 20, 2026.
This update relates to the further grants of RSUs under the 2021 and 2022 RSU Schemes and options under the Post IPO Share Option Scheme announced on June 29, 2026. All other terms and information from that earlier announcement remain unchanged and continue to apply.
Ascentage Pharma Group International reported new equity incentives for staff, directors and a consultant under its share schemes. The Board granted 440,743 RSUs under the 2021 RSU Scheme and 3,223,685 RSUs under the 2022 RSU Scheme, together representing about 0.98% of the company’s issued share capital as of the announcement date. It also granted 690,045 share options under the Post IPO Share Option Scheme, equal to about 0.18% of issued shares, with an exercise price of HK$33.62 and a ten-year term.
The RSUs are granted at no purchase price and generally vest based on Board‑set schedules, subject to satisfactory annual performance reviews and clawback provisions for misconduct or early departure. The options vest in tranches between July 2026 and June 2030. The Board and Remuneration Committee state these grants are on normal commercial terms and aim to reward contributions, retain key personnel and align them with the Group’s long‑term development.
ASCENTAGE PHARMA GROUP INTERNATIONAL officer Miyara Faical, who serves as Chief Business Officer, has filed an insider ownership report with no trading activity disclosed. All buy, sell, acquire, dispose, exercise, gift, tax-withholding and restructuring counts are zero, indicating no share or derivative transactions in this data set.
Ascentage Pharma reported extensive new clinical data for its cancer drugs olverembatinib and lisaftoclax from 17 presentations at the EHA2026 hematology congress, including eight posters. These updates span chronic myeloid leukemia (CML), Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), chronic lymphocytic leukemia (CLL/SLL) and myeloid neoplasms.
Olverembatinib showed deep, durable responses as a second-line option for CML without T315I mutations and activity in patients resistant to multiple prior TKIs. In newly diagnosed Ph+ ALL, a registrational Phase III study reported high complete remission and MRD-negative rates with manageable safety. Combination therapy of olverembatinib and lisaftoclax in pediatric relapsed/refractory Ph+ ALL produced high response and MRD-negativity rates. Lisaftoclax also delivered promising real-world efficacy in myeloid neoplasms and meaningful activity in BTKi-refractory CLL/SLL, with analyses linking genetic risk factors to shorter progression-free survival. Both drugs are approved in China but remain investigational in the US.
Ascentage Pharma Group International reported that, on June 11, 2026, the trustee of its 2022 RSU Scheme purchased 110,000 existing shares on the market. These purchased shares, representing approximately 0.0294% of the company’s issued shares, will be used to satisfy restricted share units when they vest.
The total consideration for this purchase was about HK$3,671,094, or roughly HK$33.37 per share. After this transaction, the trustee holds 2,615,000 existing shares for the scheme. The trustee will not exercise voting rights attached to the shares it holds on trust.
Ascentage Pharma Group International reported that, on June 10, 2026, the trustee of its 2022 RSU Scheme purchased 190,000 existing shares on the market. These purchased shares, equal to approximately 0.0509% of the company’s issued share capital, will be used to satisfy restricted share units when they vest.
The total consideration for this purchase was about HK$6,418,500, at an average price of roughly HK$33.78 per share. Following this transaction, the trustee holds 2,505,000 existing shares for the 2022 RSU Scheme and will not exercise voting rights attached to these shares.
Ascentage Pharma Group International filed a Form 6-K summarizing multiple data presentations at the ASCO 2026 meeting for its oncology pipeline. The company reported its first dataset for MDM2‑p53 inhibitor alrizomadlin (APG‑115) in pediatric solid tumors, showing preliminary antitumor activity and a manageable tolerability profile. In combination with Bcl‑2 inhibitor lisaftoclax, the study reported an objective response rate of 23.5% among 17 response‑evaluable pediatric patients, including one complete response and three partial responses. Updated data for olverembatinib as second‑line therapy in chronic‑phase chronic myeloid leukemia showed a complete cytogenetic response rate of 91.3% and a major molecular response rate of 60.9% at cycle 24, with stable, manageable safety. A Phase Ib study of olverembatinib plus immunotherapy blinatumomab in CML‑LBP and Ph+ BCP‑ALL demonstrated encouraging clinical activity with minimal residual disease clearance and a safety profile consistent with the individual drugs. The company notes that alrizomadlin and olverembatinib remain under investigation and are not approved by the US FDA.